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Background
We have previously demonstrated the efficacy of HER2
specific chimeric antigen receptor (CAR) T cells in animal
models of human cancer. While HER2 CAR T cells
induced tumor regression, tumors recurred in a subset of
animals. Lytic co-targeting of the tumor endothelium
could represent a strategy that enhances tumor control.
Tumor endothelium marker 8 (TEM8) is a recently
described tumor endothelium-restricted antigen conserved
in both mice and humans that represents an attractive
antigen for vascular targeting [1].
Purpose
To test the advantage of co-targeting TEM8 in conjunc-
tion with HER2 using a T cell product expressing a novel
TEM8/HER2 bispecific CAR molecule.
Methods
We designed, in silico, a single CAR molecule with both
TEM8 and HER2-specific exodomains joined together in
tandem (thus termed TanCAR). A retroviral construct
encoding a TEM8 specific single chain variable fragment
(scFv) from the mAb SB5, a Glycine/Serine linker and a
HER2 specific scFv (mAb FRP5) exodomain, followed by a
CD28 transmembrane domain, and a CD28.CD3-zeta sig-
naling endodomain was transduced CD3/CD28-activated
T cells with RD114-pseudotyped retroviral particles to
generate TEM8/HER2 bispecific TanCAR T cells. CAR
expression was confirmed by flow cytometry. Stand-
ard immunoassays were used to test the CAR T cell
functionality.
Results
TEM8/HER2 TanCAR molecules were expressed on the
surface of up to 90% of primary T cells. Staining specific
for FRP5 and SB5 ensured the expression of the TanCAR
molecule in its entirety. TanCAR T cells selectively
recognized and killed TEM8 and HER2 positive targets
distinctly, as evidenced by the release of the immuno-
stimulatory cytokines interferon-gamma and interleukin-2
in vitro and standard 4 hour 51Cr release cytotoxicity
assays. Cytokine release and killing were significantly
enhanced when TanCAR T cells encountered both target
antigens simultaneously. The kinetics of T cell activation
followed a second order kinetic equation denoting a
superadditive or synergistic effect upon recognition of a
second antigen. Minimal activation or cytolytic activity
occurred with target negative controls or with CAR null
T cells.
Conclusion
Co-targeting the tumor and its vasculature using bispecific
TanCAR T cells could enhance activation of these cells
and potentially be used to improve tumor control with
therapeutic application in cancer patients.
Authors’ details
1Baylor College of Medicine, Houston, TX, USA. 2Brown University,
Providence, RI, USA. 3University of Florida, Gainesville, FL, USA. 4National
Cancer Institute, Frederick, MD, USA.
Published: 6 November 2014
1Baylor College of Medicine, Houston, TX, USA
Full list of author information is available at the end of the article
Byrd et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P6
http://www.immunotherapyofcancer.org/content/2/S3/P6
© 2014 Byrd et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Reference
1. Chaudhary A, Hilton MB, Seaman S, Haines DC, Stevenson S, Lemotte PK,
Tschantz WR, Zhang XM, Saha S, Fleming T, St Croix B: TEM8/ANTXR1
blockade inhibits pathological angiogenesis and potentiates tumoricidal
responses against multiple cancer types. Cancer Cell 2012, 21(2):212-26.
doi:10.1186/2051-1426-2-S3-P6
Cite this article as: Byrd et al.: Dual targeting of the tumor and its
associated vasculature using a single bispecific chimeric antigen receptor
molecule. Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):P6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Byrd et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P6
http://www.immunotherapyofcancer.org/content/2/S3/P6
Page 2 of 2
